Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of tylosin tartrate-doxycycline hydrochloride pharmaceutical composition

A technology of tylosin tartrate and doxycycline hydrochloride, applied in drug delivery, antibacterial drugs, pharmaceutical formulations, etc., can solve the problems of drug waste, affecting feed intake and drinking water of livestock and poultry, and poor palatability, etc. achieve good curative effect

Active Publication Date: 2010-06-23
PU LIKE BIO ENG
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Currently commercially available tylosin tartrate-doxycycline hydrochloride soluble powders and granules have unsatisfactory curative effects, mainly because the commercially available tylosin tartrate soluble powders and granules use drug powder as raw material, while Tylosin tartrate Both doxycycline and doxycycline hydrochloride have a strong bitter taste, resulting in poor palatability, which affects the feed intake and drinking water of livestock and poultry, especially for pigs with a more sensitive sense of smell. It is difficult to achieve an effective therapeutic dose , thereby affecting the curative effect of the drug, and causing a large amount of waste of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of tylosin tartrate-doxycycline hydrochloride pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The preparation of embodiment 1 tylosin tartrate microspheres

[0023] (1) Take 100 g of ethyl cellulose, add 1000 ml of cyclohexane, heat and stir to dissolve and make ethyl cellulose solution;

[0024] (2) Take 60 g of tylosin tartrate fine powder, disperse it uniformly in the above solution, heat to 80° C., stir for 30 min, and cool to room temperature to obtain a suspension of dispersed microspheres;

[0025] (3) The suspension of dispersed microspheres was centrifuged at 3000 rpm for 20 min, filtered and dried to obtain tylosin tartrate microspheres.

[0026] The tylosin tartrate microspheres were tested and found to have good roundness and good dispersibility in aqueous solution, with an average particle size of 38.5 μm, and 87% of the microspheres had a particle size distribution range of 60 to 180 μm. The encapsulation efficiency is 52.6%, and the drug loading is 28.4%.

Embodiment 2

[0027] The preparation of embodiment 2 tylosin tartrate microspheres

[0028] (1) Take polyethylene glycol-4000 140g, heat and stir with 2400ml ethanol to dissolve, prepare PEG solution;

[0029] (2) Heat and melt 40g of paraffin wax, add 60g of tylosin tartrate powder, stir quickly and evenly disperse in the above solution while hot, stir at 80°C for 30min, cool to room temperature to obtain a suspension;

[0030] (3) The suspension of dispersed microspheres was centrifuged at 3000 rpm for 20 min, filtered, washed with petroleum ether, and dried to obtain tylosin tartrate microspheres.

[0031] The tylosin tartrate microspheres were tested and found to have good roundness and good dispersibility in aqueous solution, with an average particle size of 22.4 μm, and microspheres with a particle size distribution range of 60 to 180 μm accounted for 76% of the total. The encapsulation efficiency is 71.2%, and the drug loading is 21.6%.

Embodiment 3

[0032] The preparation of embodiment 3 doxycycline hydrochloride microspheres

[0033] (1) Take polyethylene glycol-4000 40g, heat and stir with 600ml ethanol to dissolve, prepare PEG solution;

[0034] (2) Take 10 g of paraffin and heat to melt, add 35 g of doxycycline hydrochloride powder, stir quickly and evenly disperse in the above solution while hot, stir at 80°C for 30 min, cool to room temperature to obtain a suspension;

[0035] (3) The suspension of dispersed microspheres was centrifuged at 3000 rpm for 20 min, filtered, washed with petroleum ether, and dried to obtain doxycycline hydrochloride microspheres.

[0036] The doxycycline hydrochloride microspheres were tested and found to have good roundness and good dispersibility in aqueous solution, with an average particle size of 30.1 μm, and microspheres with a particle size distribution range of 60 to 180 μm accounted for 82% of the total. The encapsulation efficiency is 64.6%, and the drug loading is 33.2%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a preparation method of tylosin tartrate-doxycycline hydrochloride pharmaceutical composition, which comprises the following steps: dissolving a high molecular material in an organic solvent to prepare a dispersion medium; respectively adding tylosin tartrate powder and doxycycline hydrochloride powder to the dispersion medium slowly, heating, stirring, dissolving and then cooling to respectively obtain a tylosin tartrate microsphere suspension and a doxycycline hydrochloride microsphere suspension; and centrifuging, filtering, washing and drying the dispersion microsphere suspension to obtain microspheres. The weight ratio of the tylosin tartrate microspheres to the doxycycline hydrochloride microspheres is 3-4:1 counted by tylosin to doxycycline, and the microspheres are mixed uniformly and adjuvant is added to prepare soluble powder, particles and oral liquid. The pharmaceutical composition prepared in the invention has good curative effect, covers up the bitterness of the medicine, and is favorable for livestock and fowl to take.

Description

technical field [0001] The invention relates to the preparation of tylosin tartrate and doxycycline hydrochloride pharmaceutical composition. technical background [0002] The currently commercially available tylosin tartrate-doxycycline hydrochloride soluble powder or granules are mainly used to treat infectious diseases caused by Gram-positive bacteria, negative bacteria and mycoplasma in livestock and poultry, such as long-term multi-cause respiratory diseases, Pasteurellosis in chickens, mixed infection of E. coli and mycoplasma secondary to viral diseases such as Newcastle disease, avian influenza, infectious bronchitis, etc.; swine asthma, infectious pleuropneumonia, pasteurellosis, dysentery, etc. Respiratory symptoms caused by stress factors such as mutation, transfer, and vaccination. [0003] Currently commercially available tylosin tartrate-doxycycline hydrochloride soluble powders and granules have unsatisfactory curative effects, mainly because the commercially...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/65A61K9/16A61K9/00A61P31/04
Inventor 张晓会刘兴金杨会鲜
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com